ELV

Comprehensive Stock Analysis: Elevance Health Inc (ELV)

Ticker: ELV | Sector: Healthcare | Market Cap: $76.61B | Price: $340.24 | Next Earnings Date: July 17, 2025

---

1. Valuation Analysis: Overvalued Relative to Growth Prospects

Elevance Health trades at a trailing P/E of 14.48 (below S&P 500 average of ~20–25), but the PEG ratio of 4.72 is a critical red flag.

• Why it matters: A PEG >1 indicates the stock is expensive relative to its earnings growth. Here, the PEG of 4.72 suggests the market is pricing in very modest growth (e.g., 5-year EPS growth of 6.81%) but expects a high price.
• Forward P/E (10.81) is even lower, signaling optimism about future earnings, but the high PEG implies this optimism is overextended.
• Key Insight: While the stock is currently undervalued vs. the S&P 500 (P/E), the PEG ratio dominates the analysis. This is a classic case of "low P/E but high PEG" – the stock is expensive for its growth trajectory. Risks: If earnings growth fails to meet expectations (next year’s growth is only +4.57%), the stock could fall sharply.

---

2. Earnings & Revenue Trends: Short-Term Dip, Long-Term Resilience

• EPS Trends:
  • TTM EPS: $23.49 (declined -8.87% YoY) – recent dip due to operational headwinds (e.g., rising premiums, cost pressures).
  • Next Year EPS Growth: +4.57% (positive but modest) – a sign of recovery.
  • 5-Year EPS Growth: +6.81% (strong, but recent slowdown is concerning).
• Revenue Trends:
  • YoY Revenue Growth (TTM): +10.21% – robust expansion driven by healthcare plan uptake.
  • 5-Year Revenue Growth: +11.15% – consistent growth in the insurance sector.
• Key Insight: The company has recovered from a recent earnings slump (EPS down 8.87% this year) but growth is slowing. The positive next-year EPS forecast suggests resilience, but the low growth rate (4.57%) aligns with the high PEG.

---

3. Dividend Profile: Strong Growth, Low Yield

• Dividend Yield: 0.2% (very low) – not suitable for income investors.
• Dividend Growth:
  • 5-Year CAGR: +15.3% (exceptional for healthcare insurance)
  • 1-Year Growth: +10.14% (strong momentum)
• Payout Ratio: 25.39% (low) – company retains most earnings for growth (ideal for long-term investors).
• Key Insight: Elevance is a dividend growth stock with a strong history, but the low yield makes it unsuitable for income-focused portfolios. The payout ratio is healthy, but the lack of dividends in the short term (due to high PEG) means the stock is more of a growth play than an income play.

---

4. Financial Health: Solid Margins, Manageable Debt

• Profit Margins:
  • Operating Margin: 4.46% (healthy for healthcare insurance)
  • Net Profit Margin: 2.83% (low but typical in insurance due to regulatory costs and claims volatility)
• Debt Metrics:
  • Total Debt-to-Equity: 0.69 (69%) – manageable (below the 1.0 threshold for high risk).
  • LT Debt-to-Equity: 0.64 (64%) – no immediate debt distress.
• Key Insight: The company has strong financial discipline (low debt, high retention of earnings) but thin margins – a common challenge in the healthcare insurance sector due to cost pressures and regulatory complexity.

---

5. Market Sentiment & Trading Dynamics

• Short Interest: 3.68% of float (low) – not a major risk (short ratio of 1.48 indicates minimal bearish pressure).
• Beta: 0.6 (less volatile than the S&P 500) – ideal for risk-averse investors.
• Recent Performance:
  • +2.28% in last trade (positive momentum).
  • RSI (14-day): 66.97 (neutral – not overbought/oversold).
  • 52-Week Range: $273.71–$510.24 (current price near the top end of the range).
• Key Insight: The stock is trading near its 52-week high with strong institutional interest (92.75% ownership). This suggests bullish sentiment but also potential overvaluation.

---

6. Sector Context & News Impact

• Healthcare Sector: Facing rising premiums, regulatory pressures, and cost inflation. Elevance benefits from rising premiums (per recent news).
• News Alert (July 17, 2025):

  "Humana Benefits From Rising Premiums Amid High Benefit Ratio" (note: ELV is Elevance Health, not Humana – likely a data error).

  • Implication: If true, rising premiums could boost Elevance’s revenue (as seen in the 10.21% YoY growth). However, the news title’s confusion with Humana (a competitor) reduces credibility.
• Key Insight: The healthcare insurance sector is growth-oriented but sensitive to regulatory changes. Elevance’s revenue growth aligns with sector trends, but the stock’s high PEG makes it vulnerable to any slowdown in premium growth.

---

7. Risk Assessment: What Could Break This Stock?

Risk Factor	Likelihood	Impact	Mitigation
Earnings miss next quarter	Medium	High (PEG >1)	Monitor Q3 earnings
Rising interest rates	Medium	Medium (low debt)	Beta 0.6 buffers volatility
Regulatory changes	High	High (sector-specific)	Strong institutional ownership
Dividend cuts	Low	Low (payout ratio is low)	Not a concern

Top Risk: The high PEG ratio (4.72) – if earnings growth fails to accelerate (e.g., next year’s growth is only +4.57%), the stock could drop 15–20% in a short period.

---

8. Conclusion & Strategic Recommendations

Overall Rating: ⚠️ Caution (High PEG, but solid fundamentals)

• For Growth Investors: ELV is a long-term play with strong revenue growth (10.21% YoY), low debt, and a history of dividend growth. However, the high PEG ratio makes it expensive relative to its growth trajectory. Target: 10–15% annual return over 3–5 years (if earnings growth accelerates).
• For Income Investors: Avoid – the 0.2% yield is too low, and the company’s low payout ratio means no near-term dividend growth.
• For Risk-Averse Investors: The low short interest (3.68%) and beta of 0.6 make it a low-volatility option, but the PEG ratio suggests it’s overpriced for the current growth outlook.

Key Action Steps:

1. Monitor Q3 2025 earnings – if EPS growth exceeds 4.57%, the stock could rebound.
2. Watch for regulatory shifts – healthcare insurance is highly sensitive to policy changes.
3. Avoid buying if PEG >3 – this stock is currently at 4.72 (overvalued).

💡 Final Thought: Elevance Health is a strong insurance company with a history of growth, but the high PEG ratio signals it’s expensive for its growth story. It’s better suited for long-term growth investors who can tolerate short-term volatility than for income-focused or short-term traders.

---

Disclaimer: This analysis is based on the provided data and does not constitute financial advice. Always conduct your own research or consult a financial advisor before making investment decisions.